Off-label prescribing of erythropoiesis-stimulating proteins in US hospitals

Drug Information Journal

Volumn 41, Issue 4, 2007, Pages 431-440

  Patkar, Anuprita ^a   Holdford, David ^b   Brophy, Donald F ^b   Pyles, Michael ^b  

^a XCENDA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Darbepoetin; Erythropoietin; Evidence based medicine; Off label; Prescribing

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER; CHRONIC KIDNEY DISEASE; CRITICAL ILLNESS; DATA BASE; DISEASE ASSOCIATION; DRUG INDICATION; HOSPITAL; HUMAN; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES;

EID: 34447282547     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150704100401     Document Type: Article

References (28)

1. Fonda D, Kiviat B. Curbing the drug marketers. Time. 2004;164(1):40.
2. Drugmakers push risky off-label uses on physicians. Knight Ridder Tribune Business News. 2003:1.
3. FDA loses hold on marketing by US drug makers. Knight Ridder Tribune Business News. 2003:1.
4. Danger AC. Read the label. Business Week. 1998(3577):100.
5. Wagner M. Hospital pharmacies watch prescriptions as debate rages over "off-label" drug use. Mod Healthc. 1992;22(19):62.
6. Wysocki B. "Wonder drug?" stops bleeding, but cost is high. Wall Street Journal. March 17, 2004:B.
7. Catherine A. Medicare vs. cancer patients; refusing to reimburse off-label treatment is far from the best way to cut costs. Business Week. 2004(3870):42.
8. Approved medicine is being used for the wrong purpose. Knight Ridder Tribune Business News. 2003:1.
9. Barrett A. "Off-label" drugs: J&J is pushing the envelope. Business Week. 2005(3930):41.
10. Neumann PJ. Why don't Americans use cost-effectiveness analysis? Am J Manag Care. 2004;10(5):308-312.
11. Levinson W, Laupacis A. A call for fairness in formulary decisions. Arch Intern Med. 2006;166(1):16-18.
12. DeWitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. Arch Intern Med. 2006;166(1):57-63.
13. Anand G. As biotech drug prices surge, US is hunting for a solution. Wall Street Journal. December 28, 2005:A1.
14. Hoffman JM, Shah ND, Vermeulen LC, Schumock GT, Grim P, Hunkler RJ, et al. Projecting future drug expenditures - 2006. Am J Health-Syst Pharm. 2006;63(2):123-138.
15. USP DI Drug Information for the Health Professional. Thomson MICROMEDEX; 2005.
16. Morreale A, Plowman B, DeLattre M, Boggie D, Schaefer M. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin. 2004;20(3):381-395.
17. Bilenker JH, Demers R, Porter DL, Wasserstein AG, Peters E, Manaker S. Recombinant human erythropoietin usage in a large academic medical center. Am J Manag Care. 2002;8:742-747.
18. Meer Van Der P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. Erythropoietin in cardiovascular diseases. Eur Heart J. 2004;25:285-291.
19. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005;293(1):90-95.
20. Wennberg JE. Practice variations and health care reform: connecting the dots. Health Aff. 2004;140-144.
21. Schrim E, Tobi H, De Jong-van den Berg LTW. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics. 2003;111(2):291-295.
22. Sugarman JH, Fleischer AB, Jr, Feldman SR. Off-label prescribing in the treatment of dermatologic disease. J Am Acad Dermatol. 2002;47(2):217-223.
23. Cuzzolin L, Zaccaron A, Fanos V. Unlicensed and off-label uses of drugs in pediatrics. Fundam Clin Pharmacol. 2003;17(1):125-131.
24. Spivak JL. Anemia in the elderly: time for new blood in old vessels? Arch Intern Med. 2005;165(19):2187-2189.
25. Morin SF, Sengupta S, Cozen M, Richards TA, Shriver MD, Palacio H, et al. Responding to racial and ethnic disparities in use of HIV drugs: analysis of state policies. Public Health Rep. 2002;117(3):263-272.
26. Nelson K, Norris K, Mangione CM. Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2002;162(8):929-935.
27. Serradell J, Galle B. Pscribing for unlabeled indications. HMO Pract. 1993;7(1):44-47.
28. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Eng J Med. 1999;340(13):409-417.